GET DAILY SIGNALSStrata Critical Medical (SRTA) Delivers +50.3% Revenue Growth in Q3
Key Takeaways
- Total revenue rose 50.3% year over year to $74.1 million, ahead of analyst consensus estimates.
- Adjusted EBITDA more than doubled to $9.6 million, with margin expanding to 13.0%.
- Free cash flow reached a record $8.6 million, highlighting the company's improving cash-generation profile.
- GAAP EPS came in at a loss of $0.09, below the consensus estimate of a $0.01 loss, due to non-cash items.
- Management reiterated full-year 2026 guidance and announced a new $20 million share repurchase authorization.
Putting the Quarter in Context
SRTA, formerly Blade Air Mobility, operates time-critical logistics and clinical services for the organ transplant ecosystem across the United States. Its third quarter, ended September 30, 2026, marks roughly one year since the company's strategic transformation and rebranding following the sale of its passenger aviation business. This report matters because it offers the clearest signal yet on whether Strata's integrated organ recovery, perfusion, and logistics platform can convert rapid revenue growth into durable margins and cash flow. With a seasonally soft transplant quarter pressuring logistics volumes, I was watching closely to see whether clinical segment share gains and expense discipline could offset that headwind and keep full-year guidance intact.
A Closer Look at the Numbers
Strata reported total revenue of $74.1 million for its third quarter of fiscal 2026, an increase of 50.3% from $49.3 million in the prior-year period and above consensus estimates. Growth was driven by the Clinical segment, where revenue climbed to $29.2 million from $2.8 million a year earlier, reflecting recent acquisitions and organic share gains. Logistics revenue declined 3.5% year over year to $44.9 million amid seasonal transplant volume declines and shorter industry-wide trip distances.
Gross profit rose 57.9% to $16.8 million, with gross margin expanding 110 basis points to 22.7%. Adjusted EBITDA jumped to $9.6 million from $4.2 million a year earlier, and adjusted EBITDA margin reached 13.0% versus 8.5% in the prior-year quarter. Operating cash flow was $9.5 million, and free cash flow hit a record $8.6 million.
On a GAAP basis, the company posted a net loss from continuing operations of $7.6 million, or $0.09 per share, compared with the consensus estimate of a $0.01 loss. Management attributed the loss entirely to non-cash, transaction-related items, including $5.5 million of intangible asset amortization, a $2.6 million fair-value adjustment on acquisition earnouts, and a $1.3 million realized loss on the sale of Joby Aviation shares received from the passenger business divestiture. To benchmark these results, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Responded
Investor reaction to the report leaned positive in early trading, with shares moving higher in pre-market action on the morning of the release. The initial response reflected a focus on the quarter's operational strengths rather than the headline GAAP loss, which management framed as the result of non-cash items tied to acquisitions and the passenger business divestiture. The record free cash flow figure, the rebound in logistics gross margin to 20.8%, and the newly announced buyback were seen as evidence of improving capital efficiency. Still, the EPS miss relative to consensus and softer logistics revenue kept some caution in place, with the central question for investors being whether clinical growth and margin gains can outrun pressure on the company's largest segment.
Looking Ahead: Guidance and What to Watch
Management reiterated its full-year 2026 guidance, calling for revenue of $285 million to $295 million, adjusted EBITDA of $33 million to $35 million, and free cash flow before aircraft and engine acquisitions of $15 million to $22 million. The midpoint implies a low single-digit sequential revenue increase in the fourth quarter, with growth expected to be led primarily by the Clinical segment while logistics stays roughly flat.
Investors should watch several items in the quarters ahead. First, clinical gross margin slipped to 25.6% as the company invested in staffing and training; management expects that figure to improve into 2027 as part-time providers are replaced with dedicated resources. Second, industry transplant volumes had not yet shown their typical seasonal rebound early in the fourth quarter, so the pace of recovery will be a key signal for logistics demand.
Longer term, Strata continues to expect 2027 growth to be driven by its Clinical division, supported by rising adoption of normothermic regional perfusion (NRP), a technique used to preserve donor organs, and third-party surgical recovery. The company also flagged a new cardiothoracic surgical staffing line and an additional $27.5 million in potential passenger-sale consideration due by early 2027. The timing and execution of M&A, alongside deployment of the $20 million buyback, remain areas for investors to monitor, though no price predictions or investment advice are implied. From what I see, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Enhancing Research with AI Tools
In my regular research process, I turn to Tickeron’s AI Screener to scan for comparable names, review technical patterns, and quickly assess fundamentals across the sector. It helps me efficiently filter thousands of stocks using customizable criteria like industry, performance metrics, and AI-driven signals, which adds useful context when evaluating companies like SRTA.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SRTA sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for SRTA moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRTA as a result. In 61 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for SRTA entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for SRTA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for SRTA just turned positive on October 20, 2026. Looking at past instances where SRTA's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.
Following a +4.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTA advanced for three days, in 204 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
SRTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.406) is normal, around the industry mean (204.027). P/E Ratio (9.061) is within average values for comparable stocks, (19.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.092) among similar stocks. P/S Ratio (1.730) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. SRTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a blank check company, which formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry HospitalNursingManagement
Advertisement